Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.

This study showed a high incidence of sunitinib-induced hematotoxicity in Japanese patients with RCC, many of whom need dose adjustment during the first cycle. Further studies should verify whether dose adjustment based on early-onset thrombocytopenia prolongs sunitinib treatment.